Rhône-Poulenc Rorer

Target entity: Rhône-Poulenc Rorer
Context triple: [Docetaxel, developedBy, Rhône-Poulenc Rorer]

• A. Smith, Kline & French
  Smith, Kline & French was a major 20th-century pharmaceutical company known for developing and marketing important prescription drugs before becoming part of GlaxoSmithKline.
• B. Schering
  Schering is a German surname most notably associated with Ernst Schering, a 19th-century pharmacist and founder of the pharmaceutical company Schering AG.
• C. Roche
  Roche is a common surname of French origin borne by various notable individuals across fields such as architecture, politics, and the arts.
• D. Roche
  Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
• E. Ciba-Geigy
  Ciba-Geigy was a major Swiss pharmaceutical and chemical company that became one of the predecessors of Novartis after its merger with Sandoz in 1996.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Rhône-Poulenc Rorer
Target entity description: Rhône-Poulenc Rorer was a major French-American pharmaceutical company known for developing important cancer therapies and later becoming part of Sanofi through mergers.

• A. Smith, Kline & French
  Smith, Kline & French was a major 20th-century pharmaceutical company known for developing and marketing important prescription drugs before becoming part of GlaxoSmithKline.
• B. Schering
  Schering is a German surname most notably associated with Ernst Schering, a 19th-century pharmacist and founder of the pharmaceutical company Schering AG.
• C. Roche
  Roche is a common surname of French origin borne by various notable individuals across fields such as architecture, politics, and the arts.
• D. Roche
  Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
• E. Ciba-Geigy
  Ciba-Geigy was a major Swiss pharmaceutical and chemical company that became one of the predecessors of Novartis after its merger with Sandoz in 1996.
• F. None of above. chosen